Provided by Tiger Fintech (Singapore) Pte. Ltd.

Compass Therapeutics, Inc.

1.75
+0.05002.94%
Post-market: 1.760.0100+0.57%19:27 EDT
Volume:691.69K
Turnover:1.20M
Market Cap:241.99M
PE:-4.87
High:1.78
Open:1.69
Low:1.68
Close:1.70
Loading ...

Major Stock Sell-Off at Compass Therapeutics by Key Directors!

TIPRANKS
·
12 Apr

Insider Moves: Key Executives Snap Up Compass Therapeutics Stock

TIPRANKS
·
09 Apr

Compass Therapeutics Price Target Maintained With a $12.00/Share by Guggenheim

Dow Jones
·
02 Apr

Compass Therapeutics Raised to Outperform From Market Perform by Leerink Partners

Dow Jones
·
02 Apr

Compass Therapeutics (CMPX) Receives a Buy from Guggenheim

TIPRANKS
·
02 Apr

Compass Therapeutics And 2 More Compelling Penny Stocks

Simply Wall St.
·
02 Apr

Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4

MT Newswires Live
·
02 Apr

Compass Therapeutics upgraded to Outperform from Market Perform at Leerink

TIPRANKS
·
02 Apr

Positive Buy Rating for Tovecimig-Paclitaxel Combo Following Promising COMPANION-002 Trial Results

TIPRANKS
·
02 Apr

Compass Therapeutics Inc. : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $6 From $4

THOMSON REUTERS
·
02 Apr

BUZZ-Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms

Reuters
·
01 Apr

Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate

MT Newswires Live
·
01 Apr

Tovecimig (Ctx-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients With Biliary Tract Cancer

THOMSON REUTERS
·
01 Apr

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

GlobeNewswire
·
01 Apr

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

GlobeNewswire
·
01 Apr

Compass Therapeutics, Inc.'s (NASDAQ:CMPX) market cap decline of US$44m may not have as much of an impact on institutional owners after a year of 0.5% returns

Simply Wall St.
·
30 Mar

With 42% stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) seems to have captured institutional investors' interest

Simply Wall St.
·
18 Mar

Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Analysts’ Top Healthcare Picks: Compass Therapeutics (CMPX), LENSAR (LNSR)

TIPRANKS
·
28 Feb

Compass Therapeutics Q4 EPS $(0.11) Misses $(0.10) Estimate

Benzinga
·
27 Feb